Dapsone as a potential treatment option for Henoch-Schönlein Purpura (HSP)

Keum Hwa Lee, Jae Hyon Park, Dong Hyun Kim, Jimin Hwang, Goeun Lee, Jae Seok Hyun, Sung Taik Heo, Ji Hoon Choi, Minwoo Kim, Minhye Kim, Seong Il Kim, Michael Eisenhut, Andreas Kronbichler, Jae Il Shin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Henoch-Schönlein Purpura (HSP, IgA vasculitis) is an immunoglobulin A (IgA) mediated disorder characterized by systemic vasculitis with variable presentation, frequently affecting the skin, mucous membrane, joints, kidneys, and rarely lungs and the central nervous system. Interestingly, enhanced production of interleukin-8 (IL-8) levels are found during active disease and increased levels have been reported in supernatants from human umbilical venous endothelial cells after stimulation with sera from patients affected by HSP. While corticosteroid therapy is currently the recommended treatment for HSP, dapsone, an anti-leprosy agent, has also recently been suggested to have therapeutic efficacy due to its ability to suppress IL-8. Moreover, in addition to IL-8 suppression, dapsone has been reported to exert various anti-inflammatory effects by inhibiting the generation of toxic free radicals, myeloperoxidase mediated halogenation that converts H2O2 to HOCl, leukocyte chemotaxis, production of tumor necrosis factor, and other anti-inflammatory molecules. This review aims to provide a solid hypothesis for the pathogenesis of vasculitis in HSP. Moreover, we highlight potential mechanistic actions of dapsone in hopes that dapsone may be considered as an alternative viable treatment for patients affected by HSP.

Original languageEnglish
Pages (from-to)42-45
Number of pages4
JournalMedical Hypotheses
Volume108
DOIs
Publication statusPublished - 2017 Oct

Fingerprint

Schoenlein-Henoch Purpura
Dapsone
Interleukin-8
Vasculitis
Immunoglobulin A
Hope
Anti-Inflammatory Agents
Therapeutics
Leukocyte Chemotaxis
Umbilicus
Cohort Effect
Systemic Vasculitis
Aptitude
Poisons
Halogenation
Leprosy
Peroxidase
Action Potentials
Free Radicals
Adrenal Cortex Hormones

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lee, Keum Hwa ; Park, Jae Hyon ; Kim, Dong Hyun ; Hwang, Jimin ; Lee, Goeun ; Hyun, Jae Seok ; Heo, Sung Taik ; Choi, Ji Hoon ; Kim, Minwoo ; Kim, Minhye ; Kim, Seong Il ; Eisenhut, Michael ; Kronbichler, Andreas ; Shin, Jae Il. / Dapsone as a potential treatment option for Henoch-Schönlein Purpura (HSP). In: Medical Hypotheses. 2017 ; Vol. 108. pp. 42-45.
@article{bd0862bd842e446ba3fea3cf2ad1e900,
title = "Dapsone as a potential treatment option for Henoch-Sch{\"o}nlein Purpura (HSP)",
abstract = "Henoch-Sch{\"o}nlein Purpura (HSP, IgA vasculitis) is an immunoglobulin A (IgA) mediated disorder characterized by systemic vasculitis with variable presentation, frequently affecting the skin, mucous membrane, joints, kidneys, and rarely lungs and the central nervous system. Interestingly, enhanced production of interleukin-8 (IL-8) levels are found during active disease and increased levels have been reported in supernatants from human umbilical venous endothelial cells after stimulation with sera from patients affected by HSP. While corticosteroid therapy is currently the recommended treatment for HSP, dapsone, an anti-leprosy agent, has also recently been suggested to have therapeutic efficacy due to its ability to suppress IL-8. Moreover, in addition to IL-8 suppression, dapsone has been reported to exert various anti-inflammatory effects by inhibiting the generation of toxic free radicals, myeloperoxidase mediated halogenation that converts H2O2 to HOCl, leukocyte chemotaxis, production of tumor necrosis factor, and other anti-inflammatory molecules. This review aims to provide a solid hypothesis for the pathogenesis of vasculitis in HSP. Moreover, we highlight potential mechanistic actions of dapsone in hopes that dapsone may be considered as an alternative viable treatment for patients affected by HSP.",
author = "Lee, {Keum Hwa} and Park, {Jae Hyon} and Kim, {Dong Hyun} and Jimin Hwang and Goeun Lee and Hyun, {Jae Seok} and Heo, {Sung Taik} and Choi, {Ji Hoon} and Minwoo Kim and Minhye Kim and Kim, {Seong Il} and Michael Eisenhut and Andreas Kronbichler and Shin, {Jae Il}",
year = "2017",
month = "10",
doi = "10.1016/j.mehy.2017.07.018",
language = "English",
volume = "108",
pages = "42--45",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",

}

Lee, KH, Park, JH, Kim, DH, Hwang, J, Lee, G, Hyun, JS, Heo, ST, Choi, JH, Kim, M, Kim, M, Kim, SI, Eisenhut, M, Kronbichler, A & Shin, JI 2017, 'Dapsone as a potential treatment option for Henoch-Schönlein Purpura (HSP)', Medical Hypotheses, vol. 108, pp. 42-45. https://doi.org/10.1016/j.mehy.2017.07.018

Dapsone as a potential treatment option for Henoch-Schönlein Purpura (HSP). / Lee, Keum Hwa; Park, Jae Hyon; Kim, Dong Hyun; Hwang, Jimin; Lee, Goeun; Hyun, Jae Seok; Heo, Sung Taik; Choi, Ji Hoon; Kim, Minwoo; Kim, Minhye; Kim, Seong Il; Eisenhut, Michael; Kronbichler, Andreas; Shin, Jae Il.

In: Medical Hypotheses, Vol. 108, 10.2017, p. 42-45.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dapsone as a potential treatment option for Henoch-Schönlein Purpura (HSP)

AU - Lee, Keum Hwa

AU - Park, Jae Hyon

AU - Kim, Dong Hyun

AU - Hwang, Jimin

AU - Lee, Goeun

AU - Hyun, Jae Seok

AU - Heo, Sung Taik

AU - Choi, Ji Hoon

AU - Kim, Minwoo

AU - Kim, Minhye

AU - Kim, Seong Il

AU - Eisenhut, Michael

AU - Kronbichler, Andreas

AU - Shin, Jae Il

PY - 2017/10

Y1 - 2017/10

N2 - Henoch-Schönlein Purpura (HSP, IgA vasculitis) is an immunoglobulin A (IgA) mediated disorder characterized by systemic vasculitis with variable presentation, frequently affecting the skin, mucous membrane, joints, kidneys, and rarely lungs and the central nervous system. Interestingly, enhanced production of interleukin-8 (IL-8) levels are found during active disease and increased levels have been reported in supernatants from human umbilical venous endothelial cells after stimulation with sera from patients affected by HSP. While corticosteroid therapy is currently the recommended treatment for HSP, dapsone, an anti-leprosy agent, has also recently been suggested to have therapeutic efficacy due to its ability to suppress IL-8. Moreover, in addition to IL-8 suppression, dapsone has been reported to exert various anti-inflammatory effects by inhibiting the generation of toxic free radicals, myeloperoxidase mediated halogenation that converts H2O2 to HOCl, leukocyte chemotaxis, production of tumor necrosis factor, and other anti-inflammatory molecules. This review aims to provide a solid hypothesis for the pathogenesis of vasculitis in HSP. Moreover, we highlight potential mechanistic actions of dapsone in hopes that dapsone may be considered as an alternative viable treatment for patients affected by HSP.

AB - Henoch-Schönlein Purpura (HSP, IgA vasculitis) is an immunoglobulin A (IgA) mediated disorder characterized by systemic vasculitis with variable presentation, frequently affecting the skin, mucous membrane, joints, kidneys, and rarely lungs and the central nervous system. Interestingly, enhanced production of interleukin-8 (IL-8) levels are found during active disease and increased levels have been reported in supernatants from human umbilical venous endothelial cells after stimulation with sera from patients affected by HSP. While corticosteroid therapy is currently the recommended treatment for HSP, dapsone, an anti-leprosy agent, has also recently been suggested to have therapeutic efficacy due to its ability to suppress IL-8. Moreover, in addition to IL-8 suppression, dapsone has been reported to exert various anti-inflammatory effects by inhibiting the generation of toxic free radicals, myeloperoxidase mediated halogenation that converts H2O2 to HOCl, leukocyte chemotaxis, production of tumor necrosis factor, and other anti-inflammatory molecules. This review aims to provide a solid hypothesis for the pathogenesis of vasculitis in HSP. Moreover, we highlight potential mechanistic actions of dapsone in hopes that dapsone may be considered as an alternative viable treatment for patients affected by HSP.

UR - http://www.scopus.com/inward/record.url?scp=85026748450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026748450&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2017.07.018

DO - 10.1016/j.mehy.2017.07.018

M3 - Article

C2 - 29055398

AN - SCOPUS:85026748450

VL - 108

SP - 42

EP - 45

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

ER -